AstraZeneca, Merck, Novo deals boost Chinese biotech as global interest grows

South China Morning Post - Sep 29, 2026

Shares of Akeso surged after British drug maker AstraZeneca moved to advance the Chinese biotech firm’s flagship cancer drug, while a new deal from US giant Merck further underscored the sector’s global momentum amid easing fears of US curbs. AstraZeneca on Tuesday announced a US$2 billion equity investment in Florida-headquartered Summit Therapeutics, which holds the exclusive rights to develop and commercialise Akeso’s immunotherapy drug ivonescimab outside China. Summit and AstraZeneca would...

Read full article

More News

About Us
Logo

In-Depth Science delivers comprehensive and compelling news and analysis on everything science and technology, seven days a week in a reader-friendly format.

Contact us: sales[at]indepthscience.com

Copyright © 2015 - 2026 In-Depth Science. All Rights Reserved.